Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
about
Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsGlycomic Approaches for the Discovery of Targets in Gastrointestinal CancerChallenges in Antibody Development against Tn and Sialyl-Tn AntigensSerum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients.Competition between serum IgG, IgM, and IgA anti-glycan antibodiesImmunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathwayEvaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray.A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection.A Contra Capture Protein Array Platform for Studying Post-translationally Modified (PTM) Auto-antigenomes.Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review.Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis.Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.The dawn of vaccines for cancer prevention.Tumor-associated auto-antibodies as early detection markers for ovarian cancer? A prospective evaluation.
P2860
Q26739942-2C3B47EC-7269-4F33-98CC-E1D5CD17018BQ26750672-45D0A4D5-D444-4A26-9B2C-FAE66B9A6A9EQ26750872-6642D3FF-C1BE-47DF-B8A5-529BEB9F77CBQ26798183-F4EC9326-071C-44B0-ABA2-38CC0D166183Q33778489-7FF5917F-CBF6-49BA-AD04-8D2AB568AE61Q35217313-863E21E6-204E-4946-B209-F2967AC5F478Q35659223-B68503E4-5C0B-4A5D-8554-6C75AFF7C5B5Q35705462-2FD7DDF1-5D98-4FC6-A6F6-A266F798198AQ35742481-4874BFE6-9532-4C73-8318-E3960E371852Q35840714-0C613BCD-3C6D-4CFF-8E4C-584891DAB531Q36539497-AF38402C-ECF1-46AC-B65F-56CDF658C1D3Q36998188-DEE91DF8-AECD-4412-880B-C077F05A18A6Q37076880-3335D7B5-3DE5-4D23-9151-5C4AF7864745Q37660331-5610D11E-5594-4A8D-BC5E-39D53ACC604FQ37674765-33B1ECFB-7B38-42AF-84AF-571203C86F66Q38470014-C9536D32-4E3D-4FF5-AA90-23874A557756Q38780263-D7AF16EE-F5C8-4AA9-98C2-EDBEF8B0E293Q48264780-643C9E36-C2F4-4930-8194-CA0B6EE3A6B1Q49566629-23330004-22AA-431F-B428-D25668563AA0Q50145937-10FAC06F-60AE-4A56-B0EB-E94F47DAD393
P2860
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Autoantibodies to MUC1 glycope ...... ian, lung or pancreatic cancer
@en
type
label
Autoantibodies to MUC1 glycope ...... ian, lung or pancreatic cancer
@en
prefLabel
Autoantibodies to MUC1 glycope ...... ian, lung or pancreatic cancer
@en
P2093
P2860
P50
P356
P1476
Autoantibodies to MUC1 glycope ...... ian, lung or pancreatic cancer
@en
P2093
A Gentry-Maharaj
A S Nudelman
E O Fourkala
I Fentiman
P2860
P2888
P304
P356
10.1038/BJC.2013.214
P407
P50
P577
2013-05-07T00:00:00Z